These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 28056498)

  • 1. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.
    Baligar P; Kochat V; Arindkar SK; Equbal Z; Mukherjee S; Patel S; Nagarajan P; Mohanty S; Teckman JH; Mukhopadhyay A
    Hepatology; 2017 Apr; 65(4):1319-1335. PubMed ID: 28056498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1-antitrypsin by wild-type donor hepatocytes.
    Ding J; Yannam GR; Roy-Chowdhury N; Hidvegi T; Basma H; Rennard SI; Wong RJ; Avsar Y; Guha C; Perlmutter DH; Fox IJ; Roy-Chowdhury J
    J Clin Invest; 2011 May; 121(5):1930-4. PubMed ID: 21505264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice.
    Shen S; Sanchez ME; Blomenkamp K; Corcoran EM; Marco E; Yudkoff CJ; Jiang H; Teckman JH; Bumcrot D; Albright CF
    Hum Gene Ther; 2018 Aug; 29(8):861-873. PubMed ID: 29641323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-1-antitrypsin deficiency: from genoma to liver disease. PiZ mouse as model for the development of liver pathology in human.
    Giovannoni I; Callea F; Stefanelli M; Mariani R; Santorelli FM; Francalanci P
    Liver Int; 2015 Jan; 35(1):198-206. PubMed ID: 24529185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
    Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
    Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.
    Guo S; Booten SL; Aghajan M; Hung G; Zhao C; Blomenkamp K; Gattis D; Watt A; Freier SM; Teckman JH; McCaleb ML; Monia BP
    J Clin Invest; 2014 Jan; 124(1):251-61. PubMed ID: 24355919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity.
    Laffranchi M; Berardelli R; Ronzoni R; Lomas DA; Fra A
    Hum Mol Genet; 2018 May; 27(10):1785-1793. PubMed ID: 29538751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease.
    Khodayari N; Wang RL; Oshins R; Lu Y; Millett M; Aranyos AM; Mostofizadeh S; Scindia Y; Flagg TO; Brantly M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy.
    Teckman JH
    COPD; 2013 Mar; 10 Suppl 1():35-43. PubMed ID: 23527737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.
    Clark VC; Marek G; Liu C; Collinsworth A; Shuster J; Kurtz T; Nolte J; Brantly M
    J Hepatol; 2018 Dec; 69(6):1357-1364. PubMed ID: 30138687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.
    Wooddell CI; Blomenkamp K; Peterson RM; Subbotin VM; Schwabe C; Hamilton J; Chu Q; Christianson DR; Hegge JO; Kolbe J; Hamilton HL; Branca-Afrazi MF; Given BD; Lewis DL; Gane E; Kanner SB; Teckman JH
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32379724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency.
    Rudnick DA; Liao Y; An JK; Muglia LJ; Perlmutter DH; Teckman JH
    Hepatology; 2004 Apr; 39(4):1048-55. PubMed ID: 15057909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous α1-antitrypsin Z allele mutation in presumed healthy donor livers used for transplantation.
    Roelandt P; Dobbels P; Komuta M; Corveleyn A; Emonds MP; Roskams T; Aerts R; Monbaliu D; Libbrecht L; Laleman W; Verslype C; Van Steenbergen W; van der Merwe S; Pirenne J; Nevens F; Cassiman D
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1335-9. PubMed ID: 23660934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype.
    Bjursell M; Porritt MJ; Ericson E; Taheri-Ghahfarokhi A; Clausen M; Magnusson L; Admyre T; Nitsch R; Mayr L; Aasehaug L; Seeliger F; Maresca M; Bohlooly-Y M; Wiseman J
    EBioMedicine; 2018 Mar; 29():104-111. PubMed ID: 29500128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte proteomes reveal the role of protein disulfide isomerase 4 in alpha 1-antitrypsin deficiency.
    Karatas E; Raymond AA; Leon C; Dupuy JW; Di-Tommaso S; Senant N; Collardeau-Frachon S; Ruiz M; Lachaux A; Saltel F; Bouchecareilh M
    JHEP Rep; 2021 Aug; 3(4):100297. PubMed ID: 34151245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.
    Song CQ; Wang D; Jiang T; O'Connor K; Tang Q; Cai L; Li X; Weng Z; Yin H; Gao G; Mueller C; Flotte TR; Xue W
    Hum Gene Ther; 2018 Aug; 29(8):853-860. PubMed ID: 29597895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    Turner AM; Stolk J; Bals R; Lickliter JD; Hamilton J; Christianson DR; Given BD; Burdon JG; Loomba R; Stoller JK; Teckman JH
    J Hepatol; 2018 Aug; 69(2):378-384. PubMed ID: 29572094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Autophagy Pathway: A Critical Route in the Disposal of Alpha 1-Antitrypsin Aggregates That Holds Many Mysteries.
    Leon C; Bouchecareilh M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant disulphide bonding contributes to the ER retention of alpha1-antitrypsin deficiency variants.
    Ronzoni R; Berardelli R; Medicina D; Sitia R; Gooptu B; Fra AM
    Hum Mol Genet; 2016 Feb; 25(4):642-50. PubMed ID: 26647313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.
    Aghajan M; Guo S; Monia BP
    Methods Mol Biol; 2017; 1639():127-138. PubMed ID: 28752452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.